Abstract
Active epidermal growth factor receptor (EGFR) mutations predict sensitivity to EGFR tyrosine kinase inhibitors (TKIs). Central nervous system (CNS) metastases are a frequent and severe complication associated with EGFR-mutated non-small cell lung cancer (NSCLC). The novel third-generation EGFR-TKI aumolertinib has shown good CNS penetration and acceptable safety profile according to clinical trials.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
